BIOMAT Database Logo BIOMAT Database Logo

Reversible congenital neutropenia associated with maternal sulphasalazine therapy. 1988

S Levi, and M Liberman, and A J Levi, and I Bjarnason

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D008431 Maternal-Fetal Exchange Exchange of substances between the maternal blood and the fetal blood at the PLACENTA via PLACENTAL CIRCULATION. The placental barrier excludes microbial or viral transmission. Transplacental Exposure,Exchange, Maternal-Fetal,Exposure, Transplacental,Maternal Fetal Exchange
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias
D012460 Sulfasalazine A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) Salicylazosulfapyridine,Asulfidine,Azulfadine,Azulfidine,Azulfidine EN,Colo-Pleon,Pleon,Pyralin EN,Salazopyrin,Salazosulfapyridine,Sulfasalazin medac,Sulfasalazin-Heyl,Sulfasalazine FNA,Sulphasalazine,Ucine,Ulcol,ratio-Sulfasalazine,Colo Pleon,Sulfasalazin Heyl,ratio Sulfasalazine

Related Publications

S Levi, and M Liberman, and A J Levi, and I Bjarnason
Reversible neutropenia associated with ampicillin therapy in pediatric patients.
October 1981, Drug intelligence & clinical pharmacy,
S Levi, and M Liberman, and A J Levi, and I Bjarnason
Reversible pulmonary disease and eosinophilia associated with sulphasalazine.
April 1988, Journal of the Royal Society of Medicine,
S Levi, and M Liberman, and A J Levi, and I Bjarnason
Reversible pulmonary disease and eosinophilia associated with sulphasalazine.
September 1988, Journal of the Royal Society of Medicine,
S Levi, and M Liberman, and A J Levi, and I Bjarnason
Agranulocytosis associated with sulphasalazine therapy.
September 1973, Postgraduate medical journal,
S Levi, and M Liberman, and A J Levi, and I Bjarnason
Agranulocytosis associated with sulphasalazine ('Salazopyrin') therapy.
June 1963, Lancet (London, England),
S Levi, and M Liberman, and A J Levi, and I Bjarnason
Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy.
December 2006, Rheumatology international,
S Levi, and M Liberman, and A J Levi, and I Bjarnason
Multiple congenital malformations associated with maternal isotretinoin therapy.
September 1984, Pediatrics,
S Levi, and M Liberman, and A J Levi, and I Bjarnason
Neutropenia in patients with rheumatoid arthritis, treated with sulphasalazine.
October 1990, British journal of rheumatology,
S Levi, and M Liberman, and A J Levi, and I Bjarnason
Neutropenia in patients with inflammatory arthritis treated with sulphasalazine.
September 1986, Annals of the rheumatic diseases,
S Levi, and M Liberman, and A J Levi, and I Bjarnason
TCIRG1-associated congenital neutropenia.
July 2014, Human mutation,
Copied contents to your clipboard!